Deferasirox Supply Across Africa
DEFRATAJ — WHO-GMP Deferasirox dispersible tablets, supplied direct from the manufacturer.
Supply & Market
Across Africa, transfusion-dependent disorders - particularly sickle-cell disease and beta-thalassemia - impose a substantial iron-overload burden on patients and health systems. Affordable, regulator-aligned access to iron chelation is a public-health priority. Taj Pharma supplies DEFRATAJ Deferasirox dispersible tablets to public-sector tenders, NGO programmes and private importers across the continent.
We hold safety stock of DEFRATAJ in the most-requested strengths for rapid sample dispatch and bridging supply. Full PO quantities are released against agreed lead times, with weekly status updates. Logistics options include FOB Mumbai/Nhava Sheva, CIF major African ports, and DDP delivery via experienced freight partners. Multilingual artwork (English, French, Portuguese, Arabic) and country-specific GTIN coding are supported.
Our regulatory affairs team supplies Module 1-5 CTD dossiers compatible with WHO-PQ aligned national authorities including NAFDAC (Nigeria), PPB (Kenya), TFDA/TMDA (Tanzania), MCAZ (Zimbabwe), SAHPRA (South Africa) and others. Country-specific labelling, post-approval variations and tender documentation are part of the supply relationship. CDA-protected dossier sharing typically completes within five working days of NDA execution.